Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Veracyte, Inc.

Veracyte, Inc. (VCYT) Stock Overview

Explore Veracyte, Inc.’s financial performance, market position, analyst ratings, and future outlook.

VCYT●NASDAQ
HealthcareMedical - Diagnostics & Research
$42.31
$0.52(1.24%)
U.S. Market opens in 58h 46m

Veracyte, Inc. (VCYT)

Meyka AI Score

Z

Key Financials

Market Cap3.4B
P/E Ratio29.25
EPS (TTM)$2.00
ROE0.09%
Fundamental Analysis

AI Price Forecasts

1 Month$44.87
3 Months$72.74
1 Year Target$50.86

VCYT Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Veracyte, Inc. (NASDAQ: VCYT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Veracyte, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of VCYT on the NASDAQ shows an RSI of 35.39, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $50.86 for the NASDAQ listing.

Key metrics behind Veracyte, Inc.'s NASDAQ-traded stock include a P/E ratio of 29.25 and a market capitalization of 3.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VCYT on the NASDAQ.

Price Performance (NASDAQ: VCYT)

1-Day Change
1.20%
5-Day Change
-0.59%
1-Month Change
-28.96%
3-Month Change
-6.42%
6-Month Change
18.69%
Year-to-Date (YTD) Change
0.45%
1-Year Change
43.70%
3-Year Change
63.60%
5-Year Change
5.04%
All-Time (Max) Change
219.17%

Contact Information

https://www.veracyte.com
650 243 6300
6000 Shoreline Court, South San Francisco, CA, 94080

Company Facts

7,550 Employees
IPO DateOct 29, 2013
CountryUS
Actively Trading

Frequently Asked Questions